Skip to main content
. 2022 Nov 9;15:3483–3497. doi: 10.2147/DMSO.S387040

Table 1.

Basic Characteristics of Participants

Variables Simple T2DM (N=358) Macrovascular Complications of T2DM (N=500) P
Age, years 68 (59,76) 70(61,75) 0.164
Male, n% 192 (53.6%) 286 (57.2%) 0.299
Duration of diabetes, years 5 (2,10) 8 (5,12) <0.001
BMI,kg/m2 23.58(21.40,25.63) 24.52(22.32,26.36) <0.001
WBC,109/L 6.30 (5.10,7.60) 6.80 (5.50,8.65) <0.001
RBC,1012/L 4.39 (3.88,4.78) 4.14 (3.63,4.54) <0.001
Neutrophils,109/L 3.80 (2.90,4.90) 4.50 (3.40,6.40) <0.001
ALT, U/L 18.00 (12.50,29.53) 16.45 (12.00,26.30) 0.127
AST, U/L 18.00 (14.95,24.93) 19.00 (15.00,27.00) 0.180
Albumin, g/L 40.55 (37.3,43.3) 39.4 (36.60,42.50) 0.004
SCr,μmol/L 67.70 (55.70,83.70) 77.70 (64.20,109.40) <0.001
BUN, mmol/L 5.65 (4.60,7.23) 6.63 (5.13,9.20) <0.001
FPG, mmol/L 7.30 (6.11,9.23) 8.47 (6.77,10.32) <0.001
TG mmol/L 1.27 (0.90,1.78) 1.79 (1.24,2.53) <0.001
TC, mmol/L 4.58 (3.60,5.27) 4.50 (3.63,5.35) 0.818
HDL-C, mmol/L 2.64 (2.04,3.32) 2.46 (1.85,3.03) 0.001
INR 0.98 (0.91,1.12) 0.99 (0.92,1.13) 0.318
TyG Index 8.91±6.17 9.44±0.74 <0.001
Hypertension, n% 176 (49.2%) 376 (75.2%) <0.001
Medication history
ACEI/ARB, n% 212(59.2%) 217(43.4%) <0.001
Statins, n% 276(77.1%) 374(74.8%) 0.439
Metformin, n% 70(19.6%) 124(24.8%) 0.07
Alpha-glucosidase inhibitor, n% 74(20.7%) 127(25.4%) 0.107
Sulfonylurea, n% 66(18.4%) 86(17.2%) 0.64
Dipeptidyl peptidase 4 inhibitor, n% 20(5.6%) 17(3.4%) 0.12
Insulin, n% 80(22.3%) 142(28.4%) 0.046
Aortic calcification, n% 123(14.3%) 325(37.9%) <0.001

Note: Data are presented as median (IQR) [25th percentile, 75th percentile] or n (%).

Abbreviations: BMI, body mass index; WBC, white blood cell count; RBC, red blood cell count, ALT, alanine aminotransferase; AST, aspartate aminotransferase; Scr, blood creatinine; BUN, blood urea nitrogen; FPG, fasting blood glucose; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; INR, international normalized ratio; TyG Index, triglyceride glucose index; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin-converting enzyme inhibitors.